Immune Signatures Predict Prognosis in Localized Cancer
David S. Hsu(Duke University), Phillip G. Febbo(Veracyte (United States)), Carey K. Anders(Duke University), Chaitanya R. Acharya(Multiple Myeloma Research Foundation), Charles G. Drake(Columbia University Irving Medical Center), Bala S. Balakumaran, T. M. Clay(Duke Medical Center), Mickey K. Kim(Clemson University), Michael A. Morse(Duke Medical Center), H. Kim Lyerly(Duke University)
Cited by 47
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
|New England Journal of Medicine|2008|1.5k